Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $0.67, $0.19 better than the analyst estimate of $0.48. Revenue for the quarter came in at $151.7 million versus the consensus estimate of $120.45 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.